455 related articles for article (PubMed ID: 30200436)
1. The p53 Pathway in Glioblastoma.
Zhang Y; Dube C; Gibert M; Cruickshanks N; Wang B; Coughlan M; Yang Y; Setiady I; Deveau C; Saoud K; Grello C; Oxford M; Yuan F; Abounader R
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30200436
[TBL] [Abstract][Full Text] [Related]
2. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
3. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.
England B; Huang T; Karsy M
Tumour Biol; 2013 Aug; 34(4):2063-74. PubMed ID: 23737287
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-324-5p-CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness.
Ghatak D; Datta A; Roychowdhury T; Chattopadhyay S; Roychoudhury S
Mol Cancer Res; 2021 Oct; 19(10):1635-1650. PubMed ID: 34257080
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
[TBL] [Abstract][Full Text] [Related]
6. Role of WW domain proteins WWOX in development, prognosis, and treatment response of glioma.
Liu SY; Chiang MF; Chen YJ
Exp Biol Med (Maywood); 2015 Mar; 240(3):315-23. PubMed ID: 25432984
[TBL] [Abstract][Full Text] [Related]
7. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma.
Stegh AH; DePinho RA
Cell Cycle; 2011 Jan; 10(1):33-8. PubMed ID: 21200141
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
9. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.
Lou J; Hao Y; Lin K; Lyu Y; Chen M; Wang H; Zou D; Jiang X; Wang R; Jin D; Lam EW; Shao S; Liu Q; Yan J; Wang X; Chen P; Zhang B; Jin B
Mol Cancer; 2020 Sep; 19(1):138. PubMed ID: 32894144
[TBL] [Abstract][Full Text] [Related]
10. A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1.
Lee JS; Xiao J; Patel P; Schade J; Wang J; Deneen B; Erdreich-Epstein A; Song HR
Neuro Oncol; 2014 Jan; 16(2):191-203. PubMed ID: 24305710
[TBL] [Abstract][Full Text] [Related]
11. Sex- and mutation-specific p53 gain-of-function activity in gliomagenesis.
Rockwell NC; Yang W; Warrington NM; Staller MV; Griffith M; Griffith OL; Gurnett CA; Cohen BA; Baldridge D; Rubin JB
Cancer Res Commun; 2021 Dec; 1(3):148-163. PubMed ID: 34957471
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.
Verreault M; Schmitt C; Goldwirt L; Pelton K; Haidar S; Levasseur C; Guehennec J; Knoff D; Labussière M; Marie Y; Ligon AH; Mokhtari K; Hoang-Xuan K; Sanson M; Alexander BM; Wen PY; Delattre JY; Ligon KL; Idbaih A
Clin Cancer Res; 2016 Mar; 22(5):1185-96. PubMed ID: 26482041
[TBL] [Abstract][Full Text] [Related]
13. RNF216 Alleviates Radiation-Induced Apoptosis and DNA Damage Through Regulating Ubiquitination-Mediated Degradation of p53 in Glioblastoma.
Xie S; Hong Z; Li Y; Wang J; Wang J; Li S; Liu Y
Mol Neurobiol; 2022 Aug; 59(8):4703-4717. PubMed ID: 35594003
[TBL] [Abstract][Full Text] [Related]
14. The Role of p53 Signaling in Colorectal Cancer.
Liebl MC; Hofmann TG
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33924934
[TBL] [Abstract][Full Text] [Related]
15. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
Xu-Monette ZY; Medeiros LJ; Li Y; Orlowski RZ; Andreeff M; Bueso-Ramos CE; Greiner TC; McDonnell TJ; Young KH
Blood; 2012 Apr; 119(16):3668-83. PubMed ID: 22275381
[TBL] [Abstract][Full Text] [Related]
16. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC
Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
20. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme.
Khatri RG; Navaratne K; Weil RJ
J Neurosurg; 2008 Nov; 109(5):842-8. PubMed ID: 18976073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
